Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion - Analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique

dc.creatorKusamura, S
dc.creatorYounan, R
dc.creatorBaratti, D
dc.creatorCostanzo, P
dc.creatorFavaro, M
dc.creatorGavazzi, C
dc.creatorDeraco, M
dc.date2006
dc.date36951
dc.date2014-11-18T18:23:10Z
dc.date2015-11-26T16:57:45Z
dc.date2014-11-18T18:23:10Z
dc.date2015-11-26T16:57:45Z
dc.date.accessioned2018-03-28T23:45:20Z
dc.date.available2018-03-28T23:45:20Z
dc.identifierCancer. John Wiley & Sons Inc, v. 106, n. 5, n. 1144, n. 1153, 2006.
dc.identifier0008-543X
dc.identifierWOS:000235822700022
dc.identifier10.1002/cncr.21708
dc.identifierhttp://www.repositorio.unicamp.br/jspui/handle/REPOSIP/57613
dc.identifierhttp://www.repositorio.unicamp.br/handle/REPOSIP/57613
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/57613
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1277753
dc.descriptionBACKGROUND. The purpose of this prospective Phase II study was to analyze morbidity and mortality of cytoreductive surgery (CRS) and intraperitoneal hyperthermic perfusion (IPHP) in the treatment of peritoneal surface malignancies. METHODS. A total of 205 patients (50 with peritoneal mesothelioma, 49 with pseudomyxoma peritonei, 41 with ovarian cancer, 32 with abdominal sarcomatosis, 13 with colon cancer, 12 with gastric cancer, and 8 with carcinomatosis from other origins) underwent 209 consecutive procedures. Four patients underwent the intervention twice because of disease relapse. There were 70 men and 135 women. Mean age was 52 years (range, 22-76 yrs). CRS was performed by using peritonectomy procedures. IPHP through the closed abdomen technique was conducted with a preheated (42.5 degrees C) perfusate containing cisplatin + mitomycin C or cisplatin + doxorubicin. RESULTS. Major morbidity rate was 12%. The most significant complications were 23 anastomotic leaks or bowel perforations, 4 abdominal bleeds, and 4 sepses. Operative mortality rate was 0.9%. On logistic regression model multivariate analysis, extent of cytoreduction (odds ratio [OR], 2.88; 95% confidence interval [CI], 1.29-6.40) and dose of cisplatin for IPHP >= 240 mg (OR, 3.13; 95% Cl, 1.24-7.90) were independent risk factors for major morbidity. Ten patients presented with Grade 3 to 4 toxicity. CONCLUSIONS. CRS + IPHP presented acceptable morbidity, toxicity, and mortality rates, all of which support prospective Phase III clinical trials.
dc.description106
dc.description5
dc.description1144
dc.description1153
dc.languageen
dc.publisherJohn Wiley & Sons Inc
dc.publisherHoboken
dc.publisherEUA
dc.relationCancer
dc.relationCancer
dc.rightsfechado
dc.rightshttp://olabout.wiley.com/WileyCDA/Section/id-406071.html
dc.sourceWeb of Science
dc.subjectperitonectomy
dc.subjectintraperitoneal hyperthermic perfusion
dc.subjectmorbidity
dc.subjectInterstitial Fluid Pressure
dc.subjectColorectal-cancer
dc.subjectPseudomyxoma-peritonei
dc.subjectColonic Anastomosis
dc.subjectHeated Chemotherapy
dc.subjectComplete Resection
dc.subjectOvarian-cancer
dc.subjectCarcinomatosis
dc.subjectChemohyperthermia
dc.subjectTumors
dc.titleCytoreductive surgery followed by intraperitoneal hyperthermic perfusion - Analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución